Patents Represented by Attorney Kalow & Springut LLP

Find this attorney in the Justia Lawyer Directory

  • siRNA targeting TIE-2
    Patent number: 7615541
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: November 10, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
    Patent number: 7612196
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: November 3, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting survivin
    Patent number: 7608707
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: October 27, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
  • siRNA targeting ras-related nuclear protein
    Patent number: 7608706
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: October 27, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting kinase insert domain receptor (KDR)
    Patent number: 7605252
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: October 20, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting cAMP-specific phosphodiesterase 4D
    Patent number: 7605250
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: October 20, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting histamine receptor H1
    Patent number: 7598369
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: October 6, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting polo-like kinase-1 (PLK-1)
    Patent number: 7598370
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PLK-1.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: October 6, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting EPH receptor A3 (EPHA3)
    Patent number: 7595388
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to EPHA3.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: September 29, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting casitas B cell lymphoma-B (CBL-B)
    Patent number: 7595389
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CBL-B.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: September 29, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Modified polynucleotides for reducing off-target effects in RNA interference
    Patent number: 7595387
    Abstract: Methods and compositions for performing RNA interference with decreased off-target effects are provided The methods and compositions permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of modifications to the siRNA. Uniquely modified siRNAs have been developed that reduce off-target effects incurred in gene-silencing. The modifications comprise 2?-O-alkyl or mismatch modification(s) at specific positions on the sense and/or antisense strands.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: September 29, 2009
    Assignees: Dharmacon, Inc., Merck & Co., Inc.
    Inventors: Devin Leake, Angela Reynolds, Anastasia Khvorova, William Marshall, Peter S. Linsley
  • siRNA targeting myeloid cell leukemia sequence 1
    Patent number: 7592444
    Abstract: Efficient sequence specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology. By selecting particular siRNAs directed to myeloid cell leukemia sequence 1 by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: September 22, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
  • siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4)
    Patent number: 7592443
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: September 22, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
    Patent number: 7592442
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to RRM 2.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: September 22, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Watch
    Patent number: D600144
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: September 15, 2009
    Assignee: Cartier Creation Studio, SA
    Inventor: Jacques Diltoer
  • Spectacles
    Patent number: D601612
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: October 6, 2009
    Assignee: Cartier Creation Studio SA
    Inventor: Veronique Marchand
  • Spectacles
    Patent number: D601614
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: October 6, 2009
    Assignee: Cartier Creation Studio SA
    Inventor: Jean Mouclier
  • Jewelry ornament
    Patent number: D602805
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: October 27, 2009
    Assignee: Cartier Creation Studio SA
    Inventor: Theodora Hardy
  • Earring
    Patent number: D603289
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: November 3, 2009
    Assignee: Cartier Creation Studio SA
    Inventor: Wilfrid Lebail
  • Ring
    Patent number: D603743
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: November 10, 2009
    Assignee: Cartier Creation Studio SA
    Inventors: Nathalie Verdeille, Swan Lucia Kim